Total reimbursement for brand-name prescription drugs in Medicare Part D increased 77% between 2011 and 2015, nearly six times faster than inflation, despite a 17% decrease in the number of prescriptions, according to a report released today by the Department of Health and Human Services’ Office of Inspector General. The share of beneficiaries with at least $2,000 in annual out-of-pocket costs for brand-name drugs nearly doubled over the five-year period to 7.3%. “Generally, plan sponsors base their reimbursement amounts on the prices that manufacturers set for their drugs,” OIG said. “Therefore, increasing manufacturer prices for brand-name drugs may result in increasing costs for Medicare and its beneficiaries, especially those beneficiaries who need access to expensive maintenance drugs.”

Related News Articles

Headline
The Medicare Hospital Insurance Trust Fund will have sufficient funds to pay full benefits until 2026, according to the latest annual report from the Medicare…
Headline
The Centers for Medicare…
Headline
The House Ways and Means Committee today approved the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act (H.R. 2113), AHA-supported…
Headline
The Senate Finance Committee held on Tuesday the third in a series of hearings on drug pricing in America, which focused on the role of pharmacy benefit…
Headline
"Medicare for All" sounds like a good idea ... but we have a better way to meet today’s challenges, create a healthier tomorrow – and advance health in America.
Headline
Beginning June 11, hospitals, physicians and other eligible providers may submit notices of intent to apply to participate in the Jan. 1, 2020 start date for…